Immunome, Inc. (NASDAQ:IMNM) Insider Acquires $149,831.40 in Stock

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) insider Robert Lechleider acquired 15,805 shares of the stock in a transaction on Thursday, November 21st. The shares were purchased at an average price of $9.48 per share, with a total value of $149,831.40. Following the completion of the transaction, the insider now owns 15,805 shares of the company's stock, valued at approximately $149,831.40. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Immunome Trading Up 13.5 %

IMNM traded up $1.33 on Monday, reaching $11.15. The stock had a trading volume of 2,245,245 shares, compared to its average volume of 779,781. The company has a market capitalization of $695.98 million, a price-to-earnings ratio of -1.37 and a beta of 1.82. Immunome, Inc. has a fifty-two week low of $6.93 and a fifty-two week high of $30.96. The firm has a 50-day moving average of $12.49 and a 200-day moving average of $13.55.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IMNM shares. Piper Sandler lowered their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Thursday, November 14th. Stephens began coverage on Immunome in a research note on Friday, November 8th. They set an "overweight" rating and a $30.00 target price for the company. Finally, Wedbush restated an "outperform" rating and issued a $33.00 price target on shares of Immunome in a research note on Friday, October 25th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $28.83.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sofinnova Investments Inc. boosted its position in Immunome by 10.3% during the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company's stock worth $7,934,000 after buying an additional 61,284 shares during the period. Cetera Investment Advisers bought a new stake in shares of Immunome in the first quarter worth $3,038,000. Victory Capital Management Inc. grew its stake in shares of Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock worth $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Immunome by 113.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company's stock valued at $55,425,000 after purchasing an additional 1,194,451 shares during the period. Finally, Ensign Peak Advisors Inc bought a new position in Immunome during the 2nd quarter worth $1,379,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.